Research

Preventing DHS in Patients With Leprosy 666
Dapsone hypersensitivity syndrome (DHS) is the most serious adverse event associated with dapsone administration and a major cause of death in patients with leprosy. In this cohort study of 1539 Chinese patients, Liu et al found that DHS did not develop in any HLA-B*13:01-negative patients treated with dapsone. Prospective HLA-B*13:01 screening may reduce DHS incidence in the Chinese population.
Editorial 655

Metastatic Melanoma Timing and Outcomes 673
Although the kinetics of metastatic disease seem to be correlated with survival, progression of the localized disease is unpredictable. In this cohort study of 638 adults with unresectable stage III or IV melanoma treated with first-line immunotherapies, targeted therapies, or chemotherapy, Vallet et al assessed whether the progression of metastatic disease was associated with the time to the first distant melanoma recurrence. They found no evidence of such association. Time to recurrence of metastatic melanoma appears unrelated to progression-free survival or overall survival. Coit provides an Editorial.
Editorial 657 Related Articles 679 and 688

Lymphatic and Hematogenous Melanoma Recurrence 679
Melanoma metastasis through lymphatic and the hematogenous pathways has been proposed, but its mechanisms not well studied. In this cohort study of patients with stage I or II melanoma, Calomarde-Rees found that age, primary tumor site and thickness, and vascular invasion were associated with lymphatic recurrence, while thickness, absence of regression, TERT promoter, and BRAF mutation were associated with hematogenous metastasis. These findings suggest that follow-up and adjuvant treatment strategies should be adapted to individual characteristics. Coit provides an Editorial.
Editorial 657 Related Articles 673 and 688

Recurrence After High-Risk Primary Melanoma 688
With systemic treatments emerging for metastatic melanoma, early detection of recurrence is increasingly important. In this cohort study of patients with high-risk primary melanoma, von Schuckmann et al evaluate recurrence patterns and report that more than 13% developed melanoma recurrence within 2 years. Most recurrences were at locoregional sites, and the others at distant sites. After surgery for locoregional recurrence, a small majority of patients remained disease free at 2 years, but about 42% developed recurrence. Understanding the patterns of melanoma recurrence can inform clinical follow-up recommendations. Coit provides an Editorial.
Editorial 657 Related Articles 673 and 679

Genetics and Psoriasis Ustekinumab Response 708
Some differential response of psoriasis to ustekinumab therapy based on HLA-C*06:02 status has been reported but generally not well studied. In this systematic review and meta-analysis, van Vugt et al found that 75% improvement rate in PASI score (PASI75) was 92% for HLA-C*06:02-positive patients and 67% for HLA-C*06:02-negative patients. Nonetheless, the authors conclude that, given the high PASI75 in both groups, there appears to be no rationale for excluding patients from ustekinumab treatment based on a negative HLA-C*06:02 status.
Continuing Medical Education jamanetwork.com/learning

Opinion

Editorial 655 Screening HLA to Prevent Severe Drug Reactions—A Devil’s Advocate Perspective
SJ Divito

657 The Changing Kinetics of Advanced Melanoma
DG Coit

660 Exploring Mental Disorders in Patients With Skin Diseases
AW Armstrong

Clinical Review & Education

JAMA Dermatology
Clinicopathological Challenge

LETTERS

Research Letter
743 Influence of “Not Relevant” Responses on the Dermatology Life Quality Index (DLQI) for Patients With Psoriasis in the United States
JS Barbieri and JM Gelfand

745 Psoriasis and Risk of Mental Disorders in Denmark
MZ Leisner and Coauthors

747 Association of Psoriasis With Mental Health Disorders in South Korea
CH Bang and Coauthors

749 Frequency of Contact Allergy to Implanted Cardiac Devices
M Gold and Coauthors

757 Correction

Departments
651 Staff Listing
708 CME Article
759 Classified Advertising
763 Contact Information
764 CME Questions

Instructions for Authors
http://jamanetwork.com/journals/jamadermatology/pages/instructions-for-authors